Nicolab Pre-IPO Investment Opportunity
Wholesale Only*
AI-assisted stroke diagnosis platform – planning to list on the ASX in H1 2027.
Increasing the speed and precision in diagnosis and treatment of stroke
Nicolabs AI-assisted platform makes stroke diagnosis and treatment faster and more accurate to deliver potentially life changing patient outcomes while saving hospitals millions and healthcare systems billions.
The technology is already deployed in 150+ hospitals across 12 countries, supporting over 70,000+ suspected stroke patients last year alone.
The company recently secured one of Australia’s largest AI health contracts, an $8m, 44-hospital deal with Queensland Health, plus contracts with Victorian Stroke Telemedicine and a national rollout underway with Health New Zealand.
With healthtech giant Philips as an equity investor and global reseller, Nicolab are now scaling into a $12.5bn target market, anticipating $40m ARR in the next two and a half years.
The company is planning a H1 2027 ASX listing in what has become one of the market’s standout sectors – medtech.
Hear more about the company
Investment
Highlights
- Technology that has delivered clinically proven results.
- Already deployed in 150+ hospitals across three continents.
- Helped 70,000+ patients last year alone.
- Now scaling into a $12.5bn market through larger contracts e.g. recent $8m+ Queensland Health deal.
- Partnerships with global giants Philips (equity investor and global reseller).
- Deep moat due to regulatory approvals and exclusive proprietary data.
- High profile board and institutional investors.
- Targeting 2027 IPO within the sought-after medtech sector.
- High level terms (see termsheet for details):
- 20-30% discount to IPO
- $100m valuation cap.
Request an Allocation
Wholesale Only*
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged by Nico.Lab International Limited and will receive fees for its role in managing this offer based on the uptake by investors. Reach Wholesale Holdings Pty Ltd and Reach Investment Group Nominees Pty Ltd, related entities of Reach Markets, hold shares and options in Nico.Lab International Limited.
*Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Any advice provided by Reach Markets, including on its website and by its representatives, is general advice only and does not consider your personal objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. You need to also read any relevant offer documents to understand the features, risks and returns associated with the investment to make your own informed decision.
Please click here to read our full general advice warning.
If you are thinking about acquiring a financial product, you should consider our Reach Markets Financial Services Guide (FSG) including the Privacy Statement.
Past performance is not a reliable indicator of future performance.